Contents

Scientific Abstracts

Welcome Address
EULAR 2023 Abstracts Reviewers

Oral Presentations

OP0001–OP0008
ABSTRACT OPENING PLENARY .................................................. 1
OP0011
Epigenetics in chronic inflammation ........................................ 8
OP0013
Precision medicine in SLE: where are we? ............................... 9
OP0014–OP0021
Adaptive immunity (T cells and B cells) in rheumatic diseases ... 10
OP0022–OP0029
Comorbidities in RMD ............................................................. 14
OP0023
Comorbidities in RMD ............................................................. 15
OP0030–OP0037
Improving our understanding of RMDs in children and young people 20
OP0038–OP0045
From hearts to lungs: comorbidities in RA .............................. 24
OP0046–OP0053
GC to new therapies .............................................................. 30
OP0054–OP0061
Clinical aspects and Treatment of axSpA: effects and predictors of effects 35
OP0062–OP0069
New clinical aspects in psoriatic arthritis ................................. 42
OP0070–OP0077
Emerging a New Era in Osteoarthritis Therapies .................... 48
OP0078–OP0085
COVID 19: A pandemic with a long tail ................................. 53
OP0084
Fibroblast activation in rheumatic diseases ............................. 64
OP0095
Autoinflammation – the next chapter .................................. 64
OP0096–OP0103
Genetics and Epigenetics of RMDs ........................................ 65
OP0104–OP0111
Innate Immunity in Pathogenesis of RMDs ......................... 70
OP0112–OP0119
Pathogenic clues to systemic sclerosis and myositis ............ 74
OP0120–OP0127
Predictors of outcome in early rheumatoid arthritis ............. 78
OP0128–OP0135
There is still a lot to SAY about biologicals for RA!............ 84
OP0136–OP0143
The future perspectives in the treatment of SLE & Sjören's ... 90
OP0144–OP0151
Risk factors and their treatment in the progression of osteoarthritis 95
OP0152–OP0159
Crystal arthritis: what is new? ............................................ 100
OP0160–OP0167
New Insights in the care and management of JIA ................. 106
OP0168–OP0175
Advances in imaging in rheumatic musculoskeletal disorders 112
OP0185–OP0186
Single-cell omics in Rheumatic diseases ............................. 122
OP0187
Spondyloarthritis across the ages ....................................... 123
OP0188
Why is performing a good systematic literature review (SLR) so difficult? 124
OP0189
Talking about Remission ...................................................... 125
OP0190
Artificial Intelligence in Medicine: Chances & Challenges .... 126
OP0193
Clinical and molecular differences across sexes in Rheumatic Disease 128
OP0194–OP0201
Pain in RMDs ................................................................. 129
OP0202–OP2009
Understanding Treatment response and novel treatment approaches in RA 133
OP0210–OP0217
Novel insights into disease taxonomy and immunophenotyping .................... 138
OP0218–OP0225
Rheumatoid arthritis: new small molecules and old DMARDs 143
OP0226–OP0233
Updates on management and outcomes in SLE and Sjögren syndrome 149
OP0234–OP0241
Update on the treatment of scleroderma lung disease ........ 154
OP0242–OP0249
Osteoporosis ................................................................. 161
OP0250–OP0257
New evidence on IgG4-related and rare autoinflammatory diseases 165
OP0258–OP0265
New insights form epidemiology and public health .................. 171
OP0266–OP0273
Epidemiology, risk and prediction of risk .............................. 176
OP0289–OP0290
The promise of health literacy in clinical care ..................... 189
OP0291
Cell activation pathways in RMDs ..................................... 190
OP0292
Inborn errors of Immunity and autoimmune / inflammatory rheumatic disorders:

What can we learn? .............................................................. 191

OP0293
Neutrophil dysregulation in systemic lupus erythematosus 191
OP0295–OP0296
Insights into gout management ....................................... 192
OP0296
Insights into gout management ....................................... 192
OP0298
Exploring the spectrum of bone inflammatory disorders across the life course 193
OP0300
Treating to Target: Challenges across the life course .......... 194
OP0301
Predicting remission and flare ......................................... 195
OP0304–OP0305
ANCA-associated vasculitis ............................................. 196
**Late breaking abstracts**

| LB0001–LB0006 | Late-Breaking Oral Abstracts ................................................. 200 |
| LB0007        | Prehabilitation to increase treatment success in rheumatology ...... 203 |
| LB0008        | Neutrophil dysregulation in systemic lupus erythematosus .......... 204 |
| LB0009        | EULAR Recommendations ...................................................... 205 |

**Poster Tours**

| POS0001–POS0009 | Adaptive immunity (T cells and B cells) in rheumatic diseases ....... 206 |
| POS010–POS0118  | Rheumatoid arthritis-aetiology, pathogenesis and animal models .. 210 |
| POS019–POS0209  | Contemporary clinical topics in psoriatic arthritis .................. 215 |
| POS030–POS0308  | RA is more than just joints ................................................ 222 |
| POS039–POS0408  | Disease mechanisms in spondyloarthritis ................................ 228 |
| POS040–POS0509  | Tapering, drug retention and predictors of response .................. 233 |
| POS082–POS090  | All about Crystal arthritis I ............................................... 253 |
| POS091–POS100  | Vessels in flares .................................................................... 259 |
| POS101–POS110  | Remarkable Findings in OA Clinical Research ........................... 263 |
| POS111–POS120  | A novel journey into SLE, Sjogren and APS .............................. 270 |
| POS121–POS131  | Outcome of scleroderma and related syndromes .......................... 277 |
| POS132–POS142  | What's new in Paediatric RMDs? ........................................... 285 |
| POS143–POS152  | Pathogenic pathways in Systemic Sclerosis and Myositis ............. 292 |
| POS153–POS162  | New developments in imaging in rheumatology ........................... 298 |
| POS163–POS172  | Systemic lupus erythematosus, Sjogren's syndrome and anti-phospholipid syndrome: clinical aspects .............................. 304 |
| POS173–POS182  | bDMARDS in RA 2.0: about the good and the bad ....................... 310 |
| POS183–POS191  | All about Crystal arthritis II ............................................... 317 |
| POS214–POS223  | People with burning vessels .................................................. 334 |
| POS224–POS233  | Treatment in psoriatic arthritis on the move ............................ 339 |
| POS234–POS243  | Innate Immunity and Autoinflammation ................................... 349 |
| POS244–POS254  | Everything you need to know about managing in axSpA ............... 356 |
| POS255–POS265  | Pain in RMDs ........................................................................ 364 |
| POS266–POS276  | All about COVID-19 in Rheumatology ...................................... 370 |
| POS277–POS287  | Advances in our care of children and young people with JIA .......... 379 |
| POS288–POS297  | Molecular and metabolic biomarkers of activity, severity and response to treatment ................................................... 385 |
| POS298–POS306  | Clinical aspects of spondyloarthritis ...................................... 391 |
| POS307–POS316  | Original perspectives on old DMARDs and new small molecules in rheumatoid arthritis .................................................. 397 |
| POS317–POS327  | Early RA and comorbidities ................................................... 404 |
| POS329–POS337  | Osteoarthritis: novel prospects ............................................. 410 |
| POS338–POS347  | Beyond the crystal ball .......................................................... 416 |
| POS348–POS358  | Genetic Determinants of Clinical Phenotypes ............................ 423 |
| POS359–POS367  | Impact of sex on disease pathogenesis and outcome .................. 430 |
| POS368–POS377  | Health, public health and health services ................................ 436 |
| POS378–POS387  | Touring the landscape of epidemiology .................................... 442 |
| POS388–POS398  | Osteoporosis .......................................................................... 448 |

**Poster View**

| POS399–POS415 | Osteoarthritis, aetiology, pathology and animal models ............... 455 |
| POS416–POS417 | Spine, mechanical musculoskeletal problems, local soft tissue disorders 463 |
| POS418–POS421 | Bone diseases, aetiology, pathology and animal models ................ 465 |
| POS422–POS441 | Spondyloarthritis - aetiology, pathogenesis and animal models ....... 467 |
| POS442–POS489 | Rheumatoid arthritis - prognosis, predictors and outcome .......... 477 |
| POS490–POS507 | Osteoporosis ........................................................................... 507 |
| POS508–POS531 | Crystal diseases, metabolic bone diseases other than osteoporosis ... 516 |
| POS532–POS535 | Infection-related rheumatic diseases ....................................... 530 |
| POS537–POS559 | COVID-19 ................................................................................ 532 |
| POS560–POS573 | Public health, health services research, and health economics ...... 547 |
| POS574–POS576 | Educational cases ..................................................................... 557 |
| POS603–POS629 | Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models ........................................ 574 |
| POS630–POS641 | Rheumatoid arthritis - biological DMARDs ............................... 590 |
| POS642–POS649 | Epidemiology, risk factors for disease or disease progression ........ 598 |
| POS650–POS692 | Spondyloarthritis - clinical aspects (other than treatment) ........ 603 |
Health Professionals in Rheumatology Abstracts

Oral Presentations

OP0012-HPR  How to treat older people with RMD  ..................................................... 8
OP0086-HPR–OP0092-HPR  Moving into better health .................................................. 59
OP0176-HPR–OP0182-HPR  Non-pharmaceutical interventions and outcomes .......... 116
OP0191-HPR  Exploring and managing inequalities in RMD healthcare ..................... 127
OP0274-HPR–OP0280-HPR  Self-management and education ........................................ 180
OP0306-HPR  Supporting patients in taking active part in their care ............................... 198

Poster Tours

POS0071-HPR–POS0081-HPR  HPR Poster Tour: Diverse interventions and patient perspectives 246
POS0203-HPR–POS0213-HPR  HPR Poster Tour: Challenges in daily life for people with RMDs 327

Poster View

POS0584-HPR  HPR Epidemiology and public health (including prevention) ................. 561
POS0585-HPR  HPR Interventions (educational, physical, social and psychological) ........ 562
POS0586-HPR  HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) ................................................................. 563
POS0587-HPR  HPR Interventions (educational, physical, social and psychological) ........ 563
POS0588-HPR–POS0594-HPR  HPR Measuring health (development and measurement properties of PROs, tests, devices) ........................................... 564
POS0595-HPR–POS0602-HPR  HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) ................................................................. 568
POS0787-HPR–POS0788-HPR  HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) ................................................................. 686
POS0789-HPR–POS0790-HPR  HPR Service developments, innovation and economics in healthcare 687
POS0791-HPR  HPR Professional education, training and competencies ............................. 688
POS0792-HPR–POS0793-HPR  HPR Interdisciplinary research ........................................... 689
POS0794-HPR–POS0798-HPR  HPR Epidemiology and public health (including prevention) 690
POS0799-HPR–POS0803-HPR  HPR Interventions (educational, physical, social and psychological) 693
POS0804-HPR–POS0805-HPR  HPR Measuring health (development and measurement properties of PROs, tests, devices) ........................................... 696
POS0988-HPR–POS0995-HPR  HPR Measuring health (development and measurement properties of PROs, tests, devices) ........................................... 810
POS0996-HPR–POS1002-HPR  HPR Epidemiology and public health (including prevention) 814
POS1003-HPR–POS1005-HPR  HPR Interventions (educational, physical, social and psychological) 817
POS1006-HPR–POS1007-HPR  HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) ................................................................. 819
POS1186-HPR–POS1198-HPR  HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) ................................................................. 926
POS1199-HPR–POS1204-HPR  HPR Service developments, innovation and economics in healthcare 932
### Oral Presentations

- **OP0009-PARE–OP0010-PARE**: "Buy one - get 4 free" - RMDs and comorbidities ........................................... 7
- **OP0093-PARE**: Let's talk about biomarkers – ask the experts .......................................................... 63
- **OP0183-PARE**: 0 – 100 in 75 minutes; RMDs have no age .......................................................... 120
- **OP0184-PARE**: E-health - possibilities and pitfalls ........................................................................... 121
- **OP0192-PARE**: Mind the gap: improving communication and outcomes ........................................ 127
- **OP0281-PARE–OP0288-PARE**: PARE Abstract Session ................................................................. 184
- **OP0299-PARE**: Pain relief - what can be done? ............................................................................. 194
- **OP0302-PARE–OP0303-PARE**: DATA MATTERS: keeping track of your health information .......... 196
- **OP0307-PARE**: “So what now?” - living and planning life while co-existing with an RMD .......... 199

### Poster Tours

- **POS0060-PARE–POS0070-PARE**: PARE Poster Tour 1 .............................................................. 241
- **POS0192-PARE–POS0202-PARE**: PARE Poster Tour 2 .............................................................. 321
Poster View
POS0577-PARE–POS0864-PARE
Patient information and education ................................................................. 558
POS0582-PARE
Building patient led organisations ................................................................. 561
POS0781-PARE–POS0784-PARE
Arthritis research ......................................................................................... 682
POS0785-PARE–POS0786-PARE
Psychosocial support .................................................................................. 684
POS0985-PARE–POS0987-PARE
Best practice campaigning ........................................................................... 809

Publication Only
AB1717-PARE–AB1718-PARE
Patient information and education ................................................................. 2095
AB1719-PARE–AB1726-PARE
Arthritis research ......................................................................................... 2096
AB1727-PARE–AB1729-PARE
Psychosocial support .................................................................................. 2101
AB1730-PARE
Arthritis research ......................................................................................... 2102
AB1731-PARE–AB1732-PARE
Patient information and education ................................................................. 2102
AB1733-PARE–AB1737-PARE
Arthritis research ......................................................................................... 2103
AB1738-PARE
Psychosocial support .................................................................................. 2106
AB1739-PARE–AB1742-PARE
Patient information and education ................................................................. 2106
AB1743-PARE–AB1745-PARE
Arthritis research ......................................................................................... 2107
AB1746-PARE–AB1749-PARE
Psychosocial support .................................................................................. 2109
AB1750-PARE–AB1751-PARE
Patient information and education ................................................................. 2110
AB1752-PARE
Arthritis research ......................................................................................... 2111
AB1753-PARE–AB1757-PARE
Psychosocial support .................................................................................. 2111

Author Index
................................................................................................................. 2160